CY1116771T1 - Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος - Google Patents

Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος

Info

Publication number
CY1116771T1
CY1116771T1 CY20111100347T CY111100347T CY1116771T1 CY 1116771 T1 CY1116771 T1 CY 1116771T1 CY 20111100347 T CY20111100347 T CY 20111100347T CY 111100347 T CY111100347 T CY 111100347T CY 1116771 T1 CY1116771 T1 CY 1116771T1
Authority
CY
Cyprus
Prior art keywords
compounds
peptide
based compounds
activities
protomase
Prior art date
Application number
CY20111100347T
Other languages
Greek (el)
English (en)
Inventor
Mark S Smyth
Guy J Laidig
Original Assignee
Onyx Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35502451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116771(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc. filed Critical Onyx Therapeutics Inc.
Publication of CY1116771T1 publication Critical patent/CY1116771T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CY20111100347T 2004-08-06 2011-04-04 Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος CY1116771T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59940104P 2004-08-06 2004-08-06
US61000104P 2004-09-14 2004-09-14
US11/106,879 US7232818B2 (en) 2004-04-15 2005-04-14 Compounds for enzyme inhibition
EP05784484A EP1781688B1 (en) 2004-08-06 2005-08-08 Compounds for proteasome enzyme inhibition

Publications (1)

Publication Number Publication Date
CY1116771T1 true CY1116771T1 (el) 2016-08-31

Family

ID=35502451

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111100347T CY1116771T1 (el) 2004-08-06 2011-04-04 Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
CY2016009C CY2016009I1 (el) 2004-08-06 2016-04-22 Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
CY181100642T CY1120677T1 (el) 2004-08-06 2018-06-20 Ενωσεις για αναστολη ενζυμου πρωτεασωματος

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2016009C CY2016009I1 (el) 2004-08-06 2016-04-22 Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
CY181100642T CY1120677T1 (el) 2004-08-06 2018-06-20 Ενωσεις για αναστολη ενζυμου πρωτεασωματος

Country Status (24)

Country Link
US (12) US7232818B2 (enExample)
EP (4) EP2266999B1 (enExample)
JP (2) JP4743720B2 (enExample)
KR (3) KR20130080064A (enExample)
CN (1) CN102286070B (enExample)
AT (1) ATE496062T1 (enExample)
AU (1) AU2005271232B2 (enExample)
BR (2) BRPI0514102B8 (enExample)
CA (1) CA2589765C (enExample)
CY (3) CY1116771T1 (enExample)
DE (1) DE602005026019D1 (enExample)
DK (2) DK3101026T3 (enExample)
ES (2) ES2525248T3 (enExample)
FR (1) FR16C0017I2 (enExample)
HU (2) HUE038005T2 (enExample)
IL (3) IL181127A (enExample)
LT (2) LT3101026T (enExample)
LU (1) LU93015I2 (enExample)
NO (2) NO341015B1 (enExample)
PL (2) PL1781688T3 (enExample)
PT (2) PT3101026T (enExample)
SG (2) SG10201701794UA (enExample)
SI (2) SI3101026T1 (enExample)
WO (1) WO2006017842A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
DE602005025750D1 (de) 2004-04-15 2011-02-17 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
WO2005111009A2 (en) * 2004-05-10 2005-11-24 Proteolix, Inc. Synthesis of amino acid keto-epoxides
CN101014612B (zh) 2004-05-10 2014-11-26 欧尼斯治疗公司 用于酶抑制的化合物
DK1830838T3 (da) 2004-12-03 2013-01-21 Dana Farber Cancer Inst Inc Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
PL2260835T3 (pl) 2004-12-07 2013-08-30 Onyx Therapeutics Inc Kompozycja do hamowania proteasomu
ES2628620T3 (es) 2005-11-09 2017-08-03 Onyx Therapeutics, Inc. Compuesto para inhibición de enzimas
MX2008016512A (es) 2006-06-19 2009-02-26 Proteolix Inc Epoxicetonas peptidicas para la inhibicion del proteasoma.
EP2040694A2 (en) * 2006-07-14 2009-04-01 VIB vzw Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
US7642369B2 (en) * 2006-09-12 2010-01-05 University Of Kentucky Research Foundation Epoxyketone-based immunoproteasome inhibitors
AU2016231532B2 (en) * 2007-10-04 2018-05-10 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2013203566B2 (en) * 2007-10-04 2016-10-13 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
PL2207791T5 (pl) * 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2009140287A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US20110009332A1 (en) * 2009-07-09 2011-01-13 Southwest Research Institute Therapeutic Treatment Of Wounds
GB0914883D0 (en) 2009-08-26 2009-09-30 Univ Belfast Compound
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
JP6042724B2 (ja) 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US9272014B2 (en) 2011-03-29 2016-03-01 Texas Tech University System Galectin-3C combination therapy for human cancer
WO2013009923A1 (en) * 2011-07-13 2013-01-17 Creighton University Methods of promoting neuron growth
WO2013071163A2 (en) 2011-11-11 2013-05-16 Millennium Pharamaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EP2776043B1 (en) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US20160008382A1 (en) 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
PL3702374T3 (pl) 2012-02-15 2022-11-21 Cydex Pharmaceuticals, Inc. Sposób wytwarzania pochodnych cyklodekstryny
ES2981576T3 (es) 2012-05-08 2024-10-09 Onyx Therapeutics Inc Métodos de formación de complejos de ciclodextrina para formular inhibidores del proteasoma de péptidos
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014015016A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CA2881986A1 (en) * 2012-08-21 2014-02-27 Fluorinov Pharma Inc. Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
UA121095C2 (uk) 2012-10-22 2020-04-10 Сідекс Фармасьютікалс, Інк. Композиції алкілованого циклодекстрину і способи їх одержання і застосування
KR102241868B1 (ko) 2013-03-13 2021-04-20 사노피 항-cd38 항체 및 카르필조밉을 포함하는 조성물
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
KR20150131276A (ko) 2013-03-14 2015-11-24 오닉스 세라퓨틱스, 인크. 디펩타이드 및 트리펩타이드 에폭시 케톤 프로테이스 억제제
EP3021862B1 (en) 2013-07-19 2017-08-30 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
WO2015032622A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
WO2015032621A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Synthesis of peptide epoxy ketones
WO2015121769A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
CN103864889B (zh) * 2014-04-04 2017-01-11 重庆泰濠制药有限公司 环氧酮化合物、其制备方法及卡非佐米的制备方法
PT3183295T (pt) 2014-08-22 2023-11-03 Cydex Pharmaceuticals Inc Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
WO2016046843A1 (en) 2014-09-24 2016-03-31 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en) 2014-10-27 2016-05-06 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
CN104402973A (zh) * 2014-11-24 2015-03-11 重庆泰濠制药有限公司 一种卡非佐米无定型晶的制备方法
CN107548400A (zh) 2014-12-02 2018-01-05 费森尤斯卡比肿瘤学有限公司 卡非佐米的纯化方法
WO2016108204A1 (en) 2014-12-31 2016-07-07 Dr. Reddy's Laboratories Limited Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
US10544189B2 (en) 2015-04-22 2020-01-28 Msn Laboratories Private Limited Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
US10364269B2 (en) 2015-05-21 2019-07-30 Laurus Labs Limited Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
CN106317188A (zh) * 2015-06-18 2017-01-11 重庆医药工业研究院有限责任公司 一种制备卡非佐米无定型物的方法
WO2017032487A1 (en) 2015-08-27 2017-03-02 Technische Universität München Proteasome inhibitor comprising a signal-emitting moiety
WO2017098532A1 (en) 2015-12-11 2017-06-15 Mylan Laboratories Limited Crystalline and amorphous forms of carfilzomib
TWI636052B (zh) * 2015-12-31 2018-09-21 中化合成生技股份有限公司 無定形卡非佐米(i)的製備方法
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
EP3494126A1 (en) 2016-08-02 2019-06-12 Synthon BV Process for making carfilzomib
LT3494108T (lt) 2016-08-05 2021-01-25 Amgen Inc. (s)-2-amino-4-metil-1-((r)-2-metiloksiran-2-il)-pentan-1-ono sintezė ir jo farmaciniu požiūriu priimtina druska
WO2018051237A1 (en) 2016-09-14 2018-03-22 Fresenius Kabi Oncology Limited A process for purification of carfilzomib intermediate
EP3512602B1 (en) 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
EP3330260A1 (en) 2016-12-01 2018-06-06 Enantia, S.L. Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
CN120884714A (zh) 2017-11-16 2025-11-04 美国安进公司 聚乙二醇化卡非佐米化合物的稳定的组合物
CN111699386B (zh) * 2017-12-08 2023-08-18 神经Gx有限责任公司 用于阿尔茨海默病的同步化细胞周期基因表达测试及相关治疗方法
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2019133988A1 (en) 2017-12-30 2019-07-04 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
US10689416B2 (en) 2017-12-30 2020-06-23 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
MX2020013853A (es) * 2018-06-22 2021-05-27 Ucl Business Ltd Compuestos innovadores.
WO2021072212A1 (en) * 2019-10-11 2021-04-15 Mayo Foundation For Medical Education And Research Proteasome inhibitors
US20230159586A1 (en) * 2020-04-21 2023-05-25 University Of Rochester Inhibitors of human epididymus protein 4
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도
TW202430548A (zh) 2022-09-29 2024-08-01 日商武田藥品工業股份有限公司 Ｃｄ３８結合融合蛋白組合療法
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN116768972A (zh) * 2023-06-25 2023-09-19 重庆药友制药有限责任公司 一种卡非佐米中间体的制备方法
WO2025035020A2 (en) 2023-08-09 2025-02-13 Amgen Inc. Methods of using carfilzomib
EP4685151A1 (en) 2024-07-24 2026-01-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Proteasome inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569748A (en) 1896-10-20 Henry edmunds
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5071957A (en) * 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US6099851A (en) * 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
WO2001028579A2 (en) 1999-10-20 2001-04-26 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
DE602005025750D1 (de) * 2004-04-15 2011-02-17 Proteolix Inc Verbindungen zur proteasomenzymhemmung
WO2005111009A2 (en) * 2004-05-10 2005-11-24 Proteolix, Inc. Synthesis of amino acid keto-epoxides
CN101014612B (zh) 2004-05-10 2014-11-26 欧尼斯治疗公司 用于酶抑制的化合物

Also Published As

Publication number Publication date
IL181127A0 (en) 2007-07-04
LT3101026T (lt) 2018-07-10
US20070191284A1 (en) 2007-08-16
HK1152716A1 (en) 2012-03-09
ES2525248T3 (es) 2014-12-19
US20160222057A1 (en) 2016-08-04
IL221572A0 (en) 2012-10-31
EP2270026A3 (en) 2011-09-14
EP3101026A1 (en) 2016-12-07
EP2266999B1 (en) 2014-09-24
BR122020008634B8 (pt) 2021-07-27
PL1781688T3 (pl) 2011-06-30
US20200071356A1 (en) 2020-03-05
AU2005271232A1 (en) 2006-02-16
US20200325172A1 (en) 2020-10-15
US20210179663A1 (en) 2021-06-17
HUS1600014I1 (hu) 2016-05-30
ATE496062T1 (de) 2011-02-15
LTC1781688I2 (lt) 2017-09-25
EP2266999A3 (en) 2011-09-14
DK1781688T3 (da) 2011-03-14
PT3101026T (pt) 2018-08-03
US7417042B2 (en) 2008-08-26
US20190211058A1 (en) 2019-07-11
HK1152536A1 (en) 2012-03-02
DE602005026019D1 (de) 2011-03-03
CA2589765A1 (en) 2006-02-16
LU93015I2 (fr) 2016-06-06
EP2266999A2 (en) 2010-12-29
US20050245435A1 (en) 2005-11-03
US7232818B2 (en) 2007-06-19
IL261892A (en) 2018-10-31
CY2016009I2 (el) 2016-08-31
KR101544258B1 (ko) 2015-08-21
IL261892B (en) 2019-12-31
FR16C0017I2 (fr) 2016-08-26
JP4743720B2 (ja) 2011-08-10
NO341015B1 (no) 2017-08-07
HUE038005T2 (hu) 2018-09-28
EP1781688B1 (en) 2011-01-19
SI3101026T1 (en) 2018-08-31
US20180170962A1 (en) 2018-06-21
HK1231491A1 (en) 2017-12-22
PT1781688E (pt) 2011-04-05
PL3101026T3 (pl) 2018-12-31
EP3101026B1 (en) 2018-03-28
CY1120677T1 (el) 2019-12-11
KR20120135355A (ko) 2012-12-12
CN102286070A (zh) 2011-12-21
BR122020008634B1 (pt) 2021-02-17
JP2008509166A (ja) 2008-03-27
AU2005271232B2 (en) 2012-07-05
CN102286070B (zh) 2014-12-10
BRPI0514102B1 (pt) 2020-07-07
EP1781688A1 (en) 2007-05-09
KR20070047780A (ko) 2007-05-07
US7491704B2 (en) 2009-02-17
NO344397B1 (no) 2019-11-25
EP2270026B1 (en) 2016-05-18
JP5394423B2 (ja) 2014-01-22
EP2270026A2 (en) 2011-01-05
CA2589765C (en) 2015-06-30
FR16C0017I1 (enExample) 2016-06-24
IL181127A (en) 2013-03-24
ES2674277T3 (es) 2018-06-28
CY2016009I1 (el) 2016-08-31
KR20130080064A (ko) 2013-07-11
SI1781688T1 (sl) 2011-05-31
JP2011148805A (ja) 2011-08-04
SG10201701794UA (en) 2017-04-27
BRPI0514102A (pt) 2008-05-27
SG155187A1 (en) 2009-09-30
NO20170381A1 (no) 2007-04-16
KR101354280B1 (ko) 2014-01-23
US20150361134A1 (en) 2015-12-17
WO2006017842A1 (en) 2006-02-16
BRPI0514102B8 (pt) 2021-05-25
LTPA2016010I1 (lt) 2016-04-25
HK1103525A1 (en) 2007-12-21
NO20070965L (no) 2007-04-16
US20220267372A1 (en) 2022-08-25
IL221572B (en) 2018-10-31
US20060030533A1 (en) 2006-02-09
DK3101026T3 (en) 2018-06-18
US20140342977A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
CY1116771T1 (el) Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
CY1115605T1 (el) Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
CY1117244T1 (el) Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
CY1119405T1 (el) Ενωση για την αναστολη ενζυμων
CY1114161T1 (el) Ενωσεις ενζυμικης αναστολης
CR9962A (es) Compuestos para inhibicion enzimatica